A director at Cel Sci Corp bought 29,197 shares at 6.850USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Summary Marketline's StemCells, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by StemCells, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and i...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases entitled “Preclinical studies of PG70 LEAPS peptide vaccine for rheumatoid arthritis”. The grant in the amount of approximately $1.5 million will provide funding to allow CEL-SCI to advance its first LEAPS product candidate, CEL-4000, towards an Investigational New Drug (IND) applicatio...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM), announces Geert Kersten, Chief Executive Officer, will present today at the 19th Annual Rodman & Renshaw Global Investment Conference at 2:10 PM. The presentation will be webcast live. To access the webcast, please visit the Investor Relations Section of CEL-SCI’s website www.cel-sci.com. The webcast replay will remain available for 90 days following the live presentation. About CEL-SCI Corporation CEL-SCI's work is focused on finding the...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM), today announced Geert Kersten, Chief Executive Officer, will be presenting at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. The presentation will be on September 11, 2017 at 2:10 PM and will be webcast live. To access the webcast, please visit the Investor Relations Section of CEL-SCI’s website w...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to December 1, 2017 (close of business). The Series DD and Series EE warrants were issued as part of a financing on December 8, 2016. Following the Company’s reverse split in June 2017, twenty-five (25) Series DD and Series EE warrants will be required to purchase one share at an exercise price of $4.50. All other terms of the warrants have remained the same. ...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American:CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $3.5 million in a registered direct offering. The closing of the offering is expected to take place on or about August 28, 2017, subject to the satisfaction of customary closing conditions. In connection with the offering, CEL-SCI will issue approximately 1,750,000 registered shares of common...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has been removed and that all clinical trial activities under this Investigational New Drug application (IND) may resume. Multikine is being studied as a potential first-line (before any other cancer treatment is given) immunotherap...
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD warrants by one month, from August 10, 2017 to September 10, 2017 (close of business). The Series DD warrants were issued as part of a financing on December 8, 2016. Following the Company’s reverse split in June 2017, twenty-five (25) Series DD warrants will be required to purchase one share at an exercise price of $4.50. All other terms of the warrants have remained the same. Abou...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.